Excelera® Specialty Pharmacy Network Announces Partnership with Smith & Nephew
ExceleraRx Corp. announced a partnership with Smith & Nephew for advanced wound care management products used in the treatment of acute and chronic wounds. These products will be made available through Excelera to health system specialty pharmacies.
MINNEAPOLIS, September 24, 2018 — The Excelera network consists of point-of-care specialty pharmacies owned by health systems and academic medical centers. The network provides members a nationally scaled infrastructure and support to help them develop best practices, gain access to limited-distribution drugs and biologics, and provide continuity of care for their patients with complex and chronic conditions requiring specialty drugs and biologics. The network also serves as a national platform for collaboration to optimize outpatient specialty drug therapy.
“According to HCUP1, one in five patients who receive debridement of a wound, burn or infection in the hospital are readmitted within 30 days,” said Mike Zagger, SVP Sales & Marketing, Smith & Nephew Advanced Wound Management. “By partnering with Excelera, we have an opportunity to help hospitals and providers deliver accurate treatment, wound management education and comprehensive care plans which may reduce the number of readmissions.”
“This partnership with Smith & Nephew is an exciting opportunity to expand our capabilities to care for a new patient base, and collaborate with additional UnityPoint Health providers,” said Ruth Coady, Executive Director of Infusion Services and Specialty Pharmacy, UnityPoint at Home. “It gives us the opportunity to coordinate care with our Wound, Ostomy and Continence Nurses (WOCN) team to improve patient outcomes where gaps in care had previously existed.”
Specialty pharmaceuticals are drugs that require special handing, storage and administration and are often used to treat the most ill and clinically complex patients. Excelera will partner with Smith & Nephew to ensure access to these important treatments is available through Excelera to health system specialty patients.
About Collagenase SANTYL◊ Ointment
SANTYL Ointment is the only FDA-approved prescription biologic indicated for debriding chronic dermal ulcers and severely burned areas. For complete prescribing information please click here.
About Smith & Nephew
Smith & Nephew is a global medical technology business dedicated to helping healthcare professionals improve people’s lives. With leadership positions in Orthopaedic Reconstruction, Advanced Wound Management, Sports Medicine and Trauma & Extremities, Smith & Nephew has around 15,000 employees and a presence in more than 100 countries. Annual sales in 2017 were almost $4.8 billion. Smith & Nephew is a member of the FTSE100 (LSE:SN, NYSE:SNN). For more information about Smith & Nephew, please visit our website http://www.smith-nephew.com, follow @SmithNephewplc on Twitter or visit SmithNephewplc on Facebook.com.
ExceleraRx Corp. supports the Excelera® Specialty Pharmacy Network, a national network of specialty pharmacies based at health systems and academic medical centers, enabling member organizations to gain access to limited distribution drugs. The Excelera network provides national-scale efficiency and collaboration to improve quality and value of outpatient specialty drug therapy for population health outcomes. Excelera’s mission is to “provide tools, technology and best practices around high-performing specialty pharmacy capabilities to network members, so that they can provide integrated, coordinated care to complex patients at the point-of-care leading to improved health outcomes and decreased healthcare costs.” For a current list of Excelera specialty pharmacy network members, or for more information about becoming a member of the Excelera network, visit excelerarx.com or follow us on LinkedIn.
This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading margins, market trends and our product pipeline are forward-looking statements. Phrases such as “aim”, “plan”, “intend”, “anticipate”, “well-placed”, “believe”, “estimate”, “expect”, “target”, “consider” and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith & Nephew, these factors include: economic and financial conditions in the markets we serve, especially those affecting health care providers, payers and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers; competition for qualified personnel; strategic actions, including acquisitions and dispositions, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organization to adapt to market developments; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith & Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith & Nephew’s most recent annual report on Form 20-F, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith & Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith & Nephew are qualified by this caution. Smith & Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith & Nephew’s expectations.
◊ Trademark of Smith & Nephew. Certain marks registered US Patent and Trademark Office
1. HCUP Statistical Briefs #153 and #154: http://www.hcup-us.ahrq.gov/reports/statbriefs/statbriefs.jsphttp://www.hcup-us.ahrq.gov/reports/statbriefs/statbriefs.jsp